Giant Recurrence Pituitary Adenoma After Three Times Transphenoidal Removal Surgery, One Craniotomy Procedure, and 30 Doses of External Radiotherapy
Abstract
Keywords
References
Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178:G1-24.
Delgado-Lopez PD, Pi-Barrio J, Duenas-Polo MT, Gordon-Bolanos MC. Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options. Clin Transl Oncol. 2018;20(10):1233-45.
Hayhurst C, Taylor PN, Lansdown AJ, Palaniappan N, Rees DA, Davies JS. Current perspectives on recurrent pituitary adenoma: The role and timing of surgery vs adjuvant treatment. Clin Endocrinol (Oxf). 2020;92(2):89-97.
Kontogeorgos G, Thodou E. Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities. Hormones (Athens). 2019;18(4):333-7.
Lin S, Zhang A, Zhang X, Wu ZB. Treatment of pituitary and other tumours with cabergoline: new mechanisms and potential broader applications. Neuroendocrinology. 2020;110(6):477-88.
Refbacks
- There are currently no refbacks.